SEARCH

SEARCH BY CITATION

References

  • Aessopos, A. & Farmakis, D. (2005) Pulmonary hypertension in beta-thalassemia. Annals NewYork Academy of Sciences, 1054, 342349.
  • Aessopos, A., Savvides, P., Stamatelos, G., Rombos, J., Tassiopoulos, T., Karagiorga, M., Kaklamanis, P. & Fessas, P. (1992) Pseudoxanthoma elasticum-like skin lesion and angiod lesions and angiod streaks in beta-thalassemia. American Journal of Hematology, 41, 159164.
  • Aessopos, A., Farmakis, D., Karagiorga, M., Voskaridou, E., Loutradi, A., Hatziliami, A., Joussef, J., Rombos, J. & Loukopoulos, D. (2001) Cardiac involvement in thalassemia intermedia: a multicenter study. Blood, 97, 34113416.
  • Aessopos, A., Farmakis, D., Deftereos, S., Tsironi, M., Polonofi, A., Moyssakis, I., Diamanti-Koudaraki, E. & Papalambros, E. (2005) Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. Annals of Hematology, 84, 353357.
  • Aessopos, A., Kati, M., Tsironi, M., Polonifi, E. & Farmakis, D. (2006) Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia. Haematologica, 91(5 Suppl.), ECR11.
  • Al-Khatti, A., Veith, R.W., Papayannopoulou, T., Fritsch, E.F., Goldwasser, E. & Stamatoyannopoulos, G. (1987) Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. New England Journal of Medicine, 317, 415420.
  • Amer, J. & Fibach, E. (2004) Oxidative status of platelets in normal and thalassemic blood. Thrombosis and Haemostasis, 92, 10521059.
  • Amer, J. & Fibach, E. (2005) Chronic oxidative stress reduces the respiratory burst response of neutrophils from beta-thalassemia patients. British Journal of Haematology, 129, 435441.
  • Arcasoy, A., Canata, D., Sinav, B., Kutlay, L., Oguz, N. & Sen, M. (2001) Serum zinc levels and zinc binding capacity in thalassemia. Journal of Trace Elements in Medicine and Biology, 15, 8587.
  • Atichartakarn, V., Chuncharunee, S., Chandanamattha, P., Likittanasombat, K. & Aryurachai, K. (2004) Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient. Blood, 103, 28442846.
  • Atweh, G.F. & Loukopoulos, D. (2001) Pharmacological induction of fetal hemoglobin in sickle cell disease and beta- thalassemia. Seminars in Hematology, 38, 367373.
  • Bank, A., Dorazio, R. & Leboulch, P. (2005) A phase I/II clinical trial of the beta-globin gene therapy for beta-thalassemia. Annals of the New York Academy of Sciences, 1054, 308316.
  • Bennett, M., Macri, C.J. & Bathgate, S.L. (2005) Erythropoietin use in a Jehovah's witness with anemia and beta-thalassemia: a case report. The Journal of Reproductive Medicine, 50, 135137.
  • Bohl, D., Bosch, A., Cardona, A., Solvetti, A. & Heard, J.M. (2000) Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood, 95, 27932798.
  • Borgna-Pignatti, C., De Stefano, P., Barone, F. & Concia, E. (1984) Penicillin compliance in splenectomized thalassemics. European Journal of Pediatrics, 142, 8385.
  • Borgna-Pignatti, C., Carnelli, V., Caruso, V., Dore, F., De Mattia, D., Di Palma, A., Di Gregorio, F., Romeo, M.A., Longhi, R., Mangiagli, A., Melevendi, C., Pizzarelli, G. & Musumeci, S. (1998) Thromboembolic events in beta thalassemia major, an Italian multicenter study. Acta Haematologica, 99, 7679.
  • Borgna-Pignatti, C., Rigon, F., Merlo, L., Chakrok, R., Micciolo, R., Perseu, L. & Galanello, R. (2003) Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica, 88, 11061109.
  • Borgna-Pignatti, C., Vergine, G., Lombardo, T., Cappellini, M.D., Cianciulli, P., Maggio, A., Renda, D., Lai, M.E., Mandas, A., Forni, G., Piga, A. & Bisconte, M.G. (2004) Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 124, 114117.
  • Bosi, G., Crepaz, R., Gamberini, M.R., Fortini, M., Scarcia, S., Bonsante, E., Pitscheider, W. & Vaccari, M. (2003) Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart, 89, 762766.
  • Bourantas, K., Economou, G. & Georgiou, J. (1997) Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. European Journal of Haematology, 58, 2225.
  • Bradai, M., Abad, M.T., Pissard, S., Lamraoui, F., Skopinski, L. & De Montalembert, M. (2003) Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood, 102, 15291530.
  • Breda, L., Gardenghi, S., Guy, E., Rachmilewitz, E.A., Weizer-Stern, O., Adamsky, K., Amariglio, N., Rechavi, G., Giardina, P.J., Grady, R.W. & Rivella, S. (2005) Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia. Annals of the New York Academy of Sciences, 1054, 417422.
  • Caglikulekci, M., Dirlik, M., Pata, C., Plasse, M., Tamer, L., Ogetman, Z. & Ercan, B. (2006) Effect of N-acetylcysteine on blood and tissue lipid peroxidation in lipopolysaccharide-induced obstructive jaundice. Journal of Investigative Surgery, 19, 175184.
  • Cao, A. (1988) Diagnosis of beta-thalassemia intermedia at presentation. Birth Defects Original Article Series, 23, 219226.
  • Cappellini, M.D., Graziadei, G., Ciceri, L., Comino, A., Bianchi, P., Porcella, A. & Fiorelli, G. (2000a) Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Molecules & Disease, 26, 105111.
  • Cappellini, M.D., Robbiolo, L., Bottasso, B.M., Coppola, R., Fiorelli, G. & Mannucci, A.P. (2000b) Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. British Journal of Haematology, 111, 467473.
  • Chaidos, A., Makis, A., Hatzimichael, E., Tsiara, S., Gouva, M., Tzouvara, E. & Bourantas, K.S. (2004) Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. Acta Haematologica, 111, 189195.
  • Chang, A.H. & Sadelain, M. (2007) The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conumdrum of the LTR, and the promise of lineage-restricted vectors. Molecular Therapy, 15, 445456.
  • Chang, J.C., Ye, L. & Kan, Y.W. (2006) Correction of the sickle cell mutation in embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 10361040.
  • Chehal, A., Aoun, E., Koussa, S., Skoury, H., Koussa, S. & Taher, A. (2003) Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine, 28, E245.
  • Chim, C.S., Kwong, Y.L., Lie, A.K., Ma, S.K., Chan, C.C., Wong, L.G., Kho, B.C., Lee, H.K., Sim, J.P., Chan, C.H., Chan, J.C., Yeung, Y.M., Law, M. & Liang, R. (2005) Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Archives of Internal Medicine, 165, 26512658.
  • Cianciulli, P., Di Toritto, T.C., Sorrentino, F., Sergiacomi, L., Massa, A. & Amadori, S. (2000) Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters. European Journal of Haematology, 64, 426429.
  • Cianciulli, P., Sorrentino, F., Maffei, L., Amadori, S., Cappabianca, M.P., Foglietta, E., Carnevali, E. & Pasquali-Ronchetti, I. (2002) Cardiovascular involvement in thalassemic patients with Pseudoxanthoma elasticum-like skin lesions. A long term follow up study. European Journal of Clinical Investigation In Press, 32, 700706.
  • Danel, P., Girot, R. & Tchernia, G. (1983) Thalassemia major manifested by megaloblastic anemia caused by folate deficiency. Archives Francaises de Pediatrie, 40, 799801.
  • Davies, J.M., Barnes, R. & Milligan, D. (2002) Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clinical Medicine, 2, 440443.
  • De Paula, E.W., Lima, C.S., Arruda, W.R., Alberto, F.L., Saad, S.T. & Costa, F.F. (2003) Long-term hydroxyurea in beta-thalassemia patients. European Journal of Haematology, 70, 151155.
  • De Stefano, P., Zecca, M., Giorgiani, G., Perotti, C., Giraldi, E. & Locatelli, F. (1999) Resolution of immune haemolytic anaemia with allogeneic bone marrow transplantation after an unsuccessful autograft. British Journal of Haematology, 106, 10631064.
  • Deane, A., Constancio, L., Fogelman, I. & Hampson, G. (2007) The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskeletal Disorders, 8, 3. doi:10.1186/1471-2474-8-3.
  • Derchi, G., Forni, G.L., Formisano, F., Cappellini, M.D., Galanello, R., D'Ascola, G., Bina, P., Magnano, C. & Lamagna, M. (2005) Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica, 90, 452458.
  • DeSimone, J., Heller, P., Hall, L. & Zwiers, D. (1982) 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proceedings of the National Academy of Sciences of the United States of America, 79, 44284431.
  • Dixit, A., Chatterjee, T.C., Mishra, P., Choudhrey, D.R., Mahapatra, M., Tyagi, S., Kabra, M., Saxsena, R. & Choudrey, W.P. (2005) Hydroxyurea in thalassemia intermedia-a promising therapy. Annals of Hematology, 84, 441446.
  • Dore, F., Cianciulli, P., Rovasio, S., Oggiano, L., Bonfigli, S., Murineddu, M., Pardini, S., Simonetti, G., Gualdi, G., Papa, G. & Longinotti, M. (1992) Incidence and clinical study of ectopic erythropoiesis in adult patients with thalassemia intermedia. Annali Italiani di Medicina Interna, 7, 137140.
  • Dore, F., Bonfigli, S., Gaviano, E., Pardini, S. & Longinotti, M. (1996) Serum tranferrin receptor levels in patients with thalassemia intermedia during rHuEPO administration. Haematologica, 81, 3739.
  • Dover, G.J. (1998) Hemoglobin switching protocols in thalassemia: experience with sodium phenylbutyrate and hydroxyurea. Annals of the New York Academy of Science, 850, 8086.
  • Eldor, A. & Rachmilewitz, E.A. (2002) The hypercoagulable state in thalassemia. Blood, 99, 3643.
  • Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. & Cabantchik, Z.I. (2003) Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood, 102, 26702677.
  • Fibach, E., Kollia, P., Schechter, A.N., Noguchi, C.T. & Rodgers, G.P. (1995) Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin. Blood, 85, 29672974.
  • De Franceschi, L., Turrini, F., Honczarenko, M., Ayi, K., Rivera, A., Fleming, M.D., Law, T., Mannu, F., Kuypers, F.A., Bast, A., Van Der Vijgh, W.J. & Brugnara, C. (2004) In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica, 89, 12871298.
  • Gabbay, E., Reed, A. & Williams, T.J. (2007) Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. Internal Medicine Journal, 37, 3848.
  • Galanello, R., Perseu, L., Giagu, N., Sole, G. & Perra, C. (2003) AHSP expression in beta thalassemia carriers with thalassemia intermedia phenotype. Blood, 102, 1881 (abstract).
  • Gamberini, M.R., Fortini, M. & De Sanctis, V. (2004) Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. Pediatric Endocrinology Reviews, 2(Suppl. 2), 319322.
  • Gardenghi, S., Marongiu, M.F., Ramos, P., Guy, E., Breda, L., Chadburn, A., Liu, Y., Amariglio, N., Rechavi, G., Rachmilewitz, E.A., Breuer, W., Cabantchik, Z.I., Wrighting, D.M., Andrews, N.C., De Sousa, M., Giardina, P.J., Grady, R.W. & Rivella, S. (2007) Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood, [Epub ahead of print] doi:10·1182/blood-2006-09-048868.
  • Glickstein, H., El, R.B., Link, G., Breuer, W., Konijn, A.M., Hershko, C., Nick, H. & Cabantchik, Z.I. (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood, 108, 31953203.
  • Gotte, P., Consolo, U., Faccioni, F. & Bertoldi, C. (2001) Associated orthodontic, surgical and hematological management of Cooley s anemia. Report of a case. Minerva Stomatologica, 50, 4754.
  • Hamlin, N., Beck, K., Baccelli, B., Cianciulli, P., Pasquali-Ronchetti, I. & Le Saux, O. (2003) Acquired pseudoxanthoma elasticum-like syndrome in beta-thalassemia patients. British Journal of Haematology, 122, 852854.
  • Hansen, K. & Singer, D.B. (2001) Asplenic-hyposplenic overwhelming sepsis, postsplenectomy sepsis revisited. Pediatric and Developmental Pathology, 4, 105121.
  • Hershko, C. (2006) Oral iron chelators: new opportunities and new dilemmas. Haematologica, 91, 13071312.
  • Hodsman, A., Papaioannou, A. & Cranney, A. (2006) Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ, 175, 48.
  • Hoppe, C., Vichinsky, E., Lewis, B., Foote, D. & Styles, L. (1999) Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. American Journal of Hematology, 62, 221227.
  • Ikeda, M., Sekimoto, M., Takiguchi, S., Kubota, M., Ikenaga, M., Yamamoto, H., Fujiwara, Y., Ohue, M., Yasuda, T., Imamura, H., Tatsuta, M., Yano, M., Furukawa, H. & Monden, M. (2005) High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Annals of Surgery, 241, 208216.
  • Jurkiewicz, M.J., Pearson, H.A. & Furlow, L.T. (1967) Surgical reconstruction of the maxilla in severe thalassemia. Plastic and Reconstructive Surgery, 39, 459464.
  • Karimi, M., Darzi, H. & Yavarian, M. (2005) Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. Journal of Pediatric Hematology/Oncology, 27, 380385.
  • Karvounis, H.I., Zaglavara, T.A., Parharidis, G.E., Nouskas, I.G., Hassapopoulou, E.P., Gemitzis, K.D. & Louridas, G.E. (2001) An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major. American Heart Journal, 141, 281.
  • Kattamis, A., Papassotiriou, I., Palaiologou, D., Apostolakou, F., Galani, A., Ladis, V., Sakellaropoulos, N. & Papanikolaou, G. (2006) The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica, 91, 809812.
  • Kumar, V. & Gruber, B. (2003) Tophaceous gout in a patient with thalassemia. Journal of Clinical Rheumatology, 9, 280284.
  • Ley, T.J., DeSimone, J., Anagnou, N.P., Keller, G.H., Humphries, R.K., Turner, T.H., Young, N.S., Keller, P. & Nienhuis, A.W. (1982) 5-Azacytidine selectively increases gamma-globin synthesis in a patients with beta+-thalassemia. New England Journal of Medicine, 307, 14691475.
  • Lialios, G., Makrydimas, G., Tsanadis, G., Lolis, D. & Bourantas, K. (2000) Effective treatment of beta-thalassemia intermedia during pregnancy with rHuEpo. A case report. Minerva Ginecologica, 52, 2931.
  • Littera, R., La Nasa, G., Derchi, G., Cappellini, M.D., Chang, C.Y. & Contu, L. (2002) Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood, 100, 15161517.
  • Locatelli, F. (2006) Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. Hematology/American Society of Hematology Education Program, 398401.
  • Loukopoulos, D., Voskaridou, E., Stamoulakatou, A., Papassotiriou, Y., Kalotychou, V., Loutradi, A., Cozma, G., Tsiarta, H. & Pavlides, N. (1998) Hydroxyurea therapy in thalassemia. Annals of the New York Academy of Sciences, 850, 120128.
  • Malik, P., Arumgam, P.I., Yee, J.K. & Puthenveetil, G. (2005) Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. Annals of the New York Academy of Sciences, 1054, 238249.
  • Mancuso, A., Maggio, A., Renda, D., Di Marzo, R. & Rigano, P. (2006) Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. British Journal of Haematology, 133, 105106.
  • Meunier, P.J. (2001) Anabolic agents for treating postmenopausal osteoporosis. Joint Bone Spine, 68, 576581.
  • Migliorati, C.A., Siegel, M.A. & Elting, L.S. (2006) Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncology, 7, 508514.
  • Mojtahedzadeh, F., Kosaryan, M., Mahdavi, M.R. & Akbari, J. (2006) The effect of folic acid supplementation in beta-thalassemia major: a randomized placebo-controlled clinical trial. Archives of Iranian Medicine, 9, 266268.
  • De Montalembert, M., Girot, R., Revillon, Y., Jan, D., Adjrad, L., Ardjoun, F.Z., Belhani, M. & Najean, Y. (1990) Partial splenectomy in homozygous beta thalassaemia. Archives of Disease in Childhood, 65, 304307.
  • Napoli, N., Carmina, E., Bucchieri, S., Sferrazza, C., Rini, G.B. & Di Fede, G. (2006) Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone, 38, 888892.
  • Nassar, A.H., Usta, I.M., Rechdan, J.B., Koussa, S., Inati, A. & Taher, A.T. (2006) Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. American Journal of Hematology, 81, 499502.
  • Nienhuis, A.W. (1981) Vitamin C and iron. New England Journal of Medicine, 304, 170171.
  • Nisli, G., Kavakli, K., Vergin, C., Oztop, S. & Cetingul, N. (1996) Recombinant human EPO trial in T.I. Journal of Tropical Pediatrics, 42, 330334.
  • Olivieri, N.F., Freedman, M.H., Perrine, S.P., Dover, G.J., Sheridan, B., Essentine, D.L. & Nagel, R.L. (1992) Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. Blood, 80, 32583260.
  • Ortuno, F., Remacha, A., Martin, S., Soler, J. & Gimferrer, E. (1990) Prevalence of folate deficiency in beta and delta-beta heterozygous thalassemia. Haematologica, 75, 585.
  • Pace, B., Li, Q., Peterson, K. & Stamatoyannopoulos, G. (1994) Alpha-amino butyric acid cannot reactivate the silenced gamma gene of the beta locus YAC transgenic mouse. Blood, 84, 43444353.
  • Pace, B.S., Shartava, A., Pack-Mabien, A., Mulekar, M., Ardia, A. & Goodman, S.R. (2003) Effects of N-acetylcysteine on dense cell formation in sickle cell disease. American Journal of Haematology, 73, 2632.
  • Paik, C.H., Alavi, I., Dunea, G. & Weiner, L. (1970) Thalassemia and gouty arthritis. The Journal of the American Medical Association, 213, 296297.
  • Panigrahi, I., Dixit, A., Arora, S., Kabra, M., Mahapatra, M., Choudhry, V.P. & Saxena, R. (2005) Do alpha deletions influence hydroxyurea response in thalassemia intermedia? Hematology, 10, 6163.
  • Papadimas, J., Goulis, D.G., Mandala, E., Georgiadis, G., Zournatzi, V., Tarlatzis, B.C. & Bontis, J.N. (2002) Beta-thalassemia and gonadal axis: a cross-sectional, clinical study in a Greek population. Hormones (Athens), 1, 179187.
  • Perrine, S.P., Miller, B.A., Greene, M.F., Cohen, R.A., Cook, N., Shackleton, C. & Faller, D.V. (1987) Butyric acid analogues augment gamma globin gene expression in neonatal erythroid progenitors. Biochemical and Biophysical Research Communications, 148, 694700.
  • Perrine, S.P., Rudolph, A., Faller, D.V., Roman, C., Cohen, R.A., Chen, S.J. & Kan, Y.W. (1988) Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proceedings of the National Academy of Sciences of the United States of America, 85, 85408542.
  • Pierre, B., Maillot, F., Casset-Sedon, D., Regina, S., Sitbon, O. & Cosnay, P. (2006) Chronic pulmonary thromboembolism revealing beta-thalassemia intermedia after splenectomy. La Revue de Medecine Interne, 27, 950953.
  • Politis, C., Spigos, D.G., Georgiopoulou, P., Vrettou, H., Economidou, I., Germenis, A.E., Richardson, C. & Papaevangelou, G. (1987) Partial splenic embolization for hypersplenism of thalassaemia major, five-year follow up. British Medical Journal, 294, 665667.
  • Pornsuriyasak, P., Suwatanapongched, T., Wangsuppasawad, N., Ngodngamthaweesuk, M. & Angchaisuksiri, P. (2006) Massive hemothorax in a beta-thalassemic patient due to spontaneous rupture of extramedullary hematopoietic masses: diagnosis and successful treatment. Respiratory Care, 51, 272276.
  • Quek, L. & Thein, S.L. (2006) Molecular therapies in β-thalassaemia. British Journal of Haematology, 136, 353365.
  • Rosen, C.J. (2005) Clinical practice. Postmenopausal osteoporosis. New England Journal of Medicine, 353, 595603.
  • Rund, D. & Rachmilewitz, E. (2000) New trends in the treatment of beta-thalassemia. Critical Reviews in Oncology/Hematology, 33, 105118.
  • Sadelain, M. (2006) Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cells anemia. Current Opinion in Hematology, 13, 142148.
  • Samakoglu, S., Lisowski, L., Budak-Alpdogan, T., Usachenko, Y., Acuto, S., Di Marzo, R., Maggio, A., Zhu, P., Tisdale, J.F., Riviere, I. & Sadelain, M. (2006) A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nature Biotechnology, 24, 8994.
  • Serjeant, G.R., Topley, J.M., Mason, K., Serjeant, B.E., Pattison, J.R., Jones, S.E. & Mohamed, R. (1981) Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet, 2, 595.
  • Sherer, D.W., Singer, G., Uribarri, J., Phelps, R.G., Sapadin, A.N., Freund, K.B., Yanuzzi, L., Fuchs, W. & Lebwohl, M. (2005) Oral phosphate binders in the treatment of pseudoxanthoma elasticum. Journal of the American Academy of Dermatology, 53, 610615.
  • Singer, S.T., Wu, V., Mignacca, R., Kuypers, F.A., Morel, P. & Vichinsky, E.P. (2000) Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, 96, 33693373.
  • Singer, S.T., Sweeters, N., Vichinsky, E.P., Wagner, A.J. & Rachmilewitz, E.A. (2003) A dose-finding and safety study of darbopoietin alfa (erythropoiesis stimulating protein) for the treatment of anemia in patients with thalassemia intermedia. Blood, 102, 268a.
  • Singer, S.T., Kuypers, F.A., Olivieri, N.F., Weatherall, D.J., Mignacca, R., Coates, T.D., Davies, S., Sweeters, N. & Vichinsky, E.P. E/beta Thalassaemia Study Group (2005) Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. British Journal of Haematology, 131, 378388.
  • Skordis, N., Christou, S., Koliou, M., Pavlides, N. & Angastiniotis, M. (1998) Fertility in female patients with thalassemia. Journal of Pediatric endocrinology & metabolism, 11, 935943.
  • Spanos, T., Karageorga, M., Ladis, V., Peristeri, J., Hatziliami, A. & Kattamis, C. (1990) Red cell alloantibodies in patients with thalassemia. Vox Sanguinis, 58, 5055.
  • Suwanmanee, T., Sierakowska, H., Fucharoen, S. & Kole, R. (2002) Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Molecular Therapy, 6, 718726.
  • Taher, A., Isma'eel, H., Mehio, G., Bignamini, D., Kattamis, A., Rachmilewitz, E.A. & Cappellini, M.D. (2006) Prevalence of thromboembolic events among 8,860 patients with thalassemia major and intermedia in the Mediterranean area and Iran. Thrombosis and Haemostasis, 96(4), 488491.
  • Tesoriere, L., D'Arpa, D., Maggio, A., Giaccone, V., Pedone, E. & Livrea, M.A. (1998) Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia. Atherosclerosis, 137, 429435.
  • Tesoriere, L., D'Arpa, D., Bufera, D., Allegra, M., Renda, D., Maggio, A., Buongiorno, A. & Livrea, M.A. (2001) Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radical Research, 34, 529540.
  • Tesoriere, L., Allegra, M., Bufera, D., Gentile, C. & Livrea, M.A. (2006) Cytoprotective effects of the antioxidant phytochemical indicaxanthin in beta-thalassemic red blood cells. Free Radical Research, 40, 753761.
  • Vento, S., Cainelli, F. & Cesario, F. (2006) Infections and thalassaemia. The Lancet Infectious Diseases, 6, 226233.
  • Vichinsky, E.P. (2004) Pulmonary hypertension in sickle cell disease. New England Journal of Medicine, 350, 857859.
  • Vogiatzi, M.G., Autio, K.A., Mait, J.E., Schneider, R., Lesser, M. & Giardina, P.J. (2005) Low bone mineral density in adolescents with beta-thalassemia. Annals of the New York Academy of Sciences, 1054, 462466.
  • Voskaridou, E., Anagnostopoulos, A., Konstantopoulos, K., Stoupa, E., Spyropoulou, E., Kiamouris, C. & Terpos, E. (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica, 91, 11931202.
  • Weinberg, R.S., Ji, X., Sutton, M., Perrine, S., Galperin, Y., Li, Q., Liebhaber, S.A., Stamatoyannopoulos, G. & Atweh, G.F. (2005) Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood, 105, 18071809.
  • Wilson, S. (2000) Acute leukemia in a patient with sickle cell anemia treated with hydroxyurea. Annals of Internal Medicine, 133, 925926.
  • Woo, G.H., Katayama, K., Bak, E.J., Ueno, M., Yamauchi, H., Uetsuka, K., Nakayama, H. & Doi, K. (2004) Effects of prenatal hydroxyurea-treatment on mouse offspring. Experimental and Toxicologic Pathology, 56, 17.
  • Wu, L.C., Sun, C.W., Ryan, T.M., Pawlik, K.M., Ren, J. & Townes, T.M. (2006) Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood, 108, 11831188.